Book Value per Share: Neurogene Corp (NGNE)

Neurogene Inc. (NGNE) - corporate logo

Neurogene Inc. (NGNE) is strengthening its position through cutting-edge developments in gene therapy for rare brain pathologies, creating high barriers to entry for competitors. This price action chart below illustrates market quotes, with the current figure standing at 13.65. Business revenues will be based on the commercialization of viral vector drugs for the treatment of Rett syndrome. The creation of unique medications will grant the firm sole-supplier status with long-term patent protection.

Neurogene Inc (NGNE) Equity per Share: for the period 02/21/2024 - 10/27/2026

neurogene.com - analytical breakdowns and key metrics (NGNE)

- price and consensus price forecast:
Price Chart Neurogene Corp|NGNE - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Neurogene Inc.|NGNE - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Neurogene|NGNE - Accounting Capitalization|Market Capitalization to Book Value Ratio neurogene.com|NGNE - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Neurogene Inc.|NGNE - Long-Term Debt to Capital|Short-Term Debt to Equity Neurogene|NGNE - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Neurogene Inc.
Fundamental company valuation:Neurogene Corp, NGNE
Manufactured products of Neurogene

Book value per share measures a company's net assets divided by the number of outstanding shares, serving as an indicator of financial stability and the real value of capital. For Neurogene Inc. (NGNE), whose success depends on FDA approvals rather than market cycles, the trend in the book value of a single common share reflects the efficiency of resource management during periods of costly clinical trials.

Competitor analysis for Neurogene Inc.

Biogen Corp (BIIB) - Net Assets per Single Share|NBIX - Equity per Share|Book Value per Share RGC|AXSM (axsome.com) - Net Asset Value per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|TRVI (Trevi Corp) - Net Asset Value per Share|Net Assets per Single Share Praxis Precision Medicines (PRAX)|Equity per Share anavex.com|CeriBell - Book Value per Share|Net Asset Value per Share Prothena Corporation PRTA|Accounting Value per Share ALEC (Alector)|Annexon Biosciences Inc. - Book Value per Share|Net Assets per Single Share Omeros Corp. (OMER)|ACIU: Accounting Value of a Share|Net Assets per Single Share VYGR|Neumora (NMRA) - Net Asset Value per Share|Scilex Holding Co. - Book Value per Share|Book Value of One Share Tevogen Bio Inc.|Alpha Cognition - Book Value per Share|Net Asset Value per Share CGTX (Cognition Therapeutics Inc.)|IKT - Net Assets per Single Share|Equity per Share Cassava Sciences Inc SAVA|ASRT (Assertio Therapeutics) - Book Value per Share|Coya Therapeutics, Inc. (COYA) - Net Asset Value per Share|Accounting Value per Share vistagen.com VTGN|Ovid Therapeutics (OVID) - Accounting Value of a Share|ABOS: Book Value per Share|Net Assets per Share CRVO|Net Assets per Single Share Alterity Therapeutics ATHE|Equity per Share clene.com (CLNN)|PepGen - Book Value per Share|JUNS - Accounting Value per Share|Accounting Value per Share RLMD (Relmada Therapeutics, Inc.)|ANVS: Net Assets per Share|Net Assets per Single Share gracetx.com|Firefly Neuro (AIFF) - Equity per Share|ANEW Medical - Book Value per Share|Book Value of One Share NRSN|Net Assets per Single Share Reviva Pharmaceuticals Holdings, Inc. RVPH|Equity per Share metaviatx.com (MTVA)|NRXS: Book Value per Share|Helius Medical Technologies, Inc. - Net Asset Value per Share|Passage Bio Corp (PASG) - Net Assets per Single Share|NEUP - Equity per Share|Book Value per Share NERV|Net Asset Value per Share Athira Pharma Inc|ADXN (Addex Therapeutics, Ltd.) - Accounting Value per Share|Book Value per Share ALZN|Cyclerion Therapeutics (CYCN) - Net Assets per Single Share|Accounting Value of a Share PTIX (protagenic.com)|KTTA: Net Assets per Single Share|Cortigent Inc - Net Asset Value per Share|Avenue Therapeutics, Inc (ATXI) - Net Assets per Single Share|BCLI - Equity per Share|Book Value per Share CARA|Net Asset Value per Share chromocell.com|ELYM (Eliem Therapeutics, Inc.) - Accounting Value per Share|Book Value per Share ITCI|Longboard Pharma (LBPH) - Net Assets per Single Share|Accounting Value of a Share MRNS (Marinus Pharma)|NKGN: Net Assets per Single Share|Net Asset Value per Share neurobopharma.com NRBO|Book Value per Share SAGE|SNPX - Book Value of One Share|Book Value per Share TRVN|VIGL (Vigil Neuroscience, Inc.) - Net Asset Value per Share|Net Assets per Single Share Anew Medical (WENA)|Equity per Share cerevel.com